Drug Profile
Zeniplatin
Alternative Names: CL 286558Latest Information Update: 29 Aug 1997
Price :
$50
*
At a glance
- Originator Wyeth
- Class Cytostatics; Platinum complexes
- Mechanism of Action DNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Malignant melanoma; Renal cancer
Most Recent Events
- 29 Aug 1997 Discontinued-II for Malignant melanoma in Norway (Injection)
- 29 Aug 1997 Discontinued-II for Renal cancer in Norway (Injection)
- 14 Mar 1995 Discontinued-II for Cancer in Australia (IV-infusion)